In this five-year prospective mono-center study, we therefore further extended the efficacy and safety data of ALZ, included all commonly used MS-related outcomes, and added data of glial fibrillary acidic protein (GFAP), reflecting astrogliosis, and neurofilament light (NfL), reflecting axonal damage, in cerebrospinal fluid (CSF) and serum. This evidence concerns the gene GFAP and myeloid sarcoma.